Mutz Christopher 4

What Happened
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), sold 5,323 shares in an open-market transaction on February 20, 2026. The sales generated approximately $415,300, based on a weighted average sales price of $78.02 per share. This was a sale (not a purchase) and therefore is typically considered a routine insider sell rather than an explicit bullish signal.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (appears timely). Accession: 0001846487-26-000006.
• Type/code: Sale (S) — open market or private sale listed on the Form 4.
• Shares sold: 5,323; weighted average price reported $78.02; proceeds ≈ $415,300.
• Price range: multiple trades at $77.20 to $78.58 (weighted average shown).
• Footnote: Sales were made pursuant to a Rule 10b5-1 trading plan adopted by Mutz on June 16, 2025 — indicating these were preplanned trades.
• Shares owned after transaction: not specified in the provided filing summary.

Context
A 10b5-1 plan lets insiders execute prearranged trades and reduces the extent to which a sale is judged as a real-time signal about company prospects. For retail investors, purchases typically carry clearer informational value than routine sales; this filing documents a planned sale rather than new insider accumulation.